[14C]-STX-478 Clinical Trials (2026): 2 Studies for Breast Cancer & Healthy
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 [14C]-STX-478 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Breast Cancer & Healthy) and 888 total planned enrollment. 1 [14C]-STX-478 clinical trial is actively recruiting at 24 U.S. sites across 16 states. Most recent activity: NCT05768139 (Jul 2030).
Where to Participate: All [14C]-STX-478 Trial Sites in the U.S. (24 sites across 16 states)
Every actively recruiting [14C]-STX-478trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Ellison Clinic at Saint John's | Los Angeles90064 | NCT05768139 | Map |
| CA | UCSF Medical Center at Mission Bay | San Francisco94143 | NCT05768139 | Map |
| CO | University of Colorado Cancer Center | Aurora80045 | NCT05768139 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05768139 | Map |
| GA | Winship Cancer Institute, Emory University | Atlanta30322 | NCT05768139 | Map |
| IA | University of Iowa | Iowa City52242 | NCT05768139 | Map |
| LA | Louisiana State University Health Sciences Center | New Orleans70112 | NCT05768139 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05768139 | Map |
| MA | Massachusetts General Hospital | Boston02115 | NCT05768139 | Map |
| MI | START Midwest | Grand Rapids49546 | NCT05768139 | Map |
| MO | Saint Luke's Cancer Institute | Kansas City64111-3220 | NCT05768139 | Map |
| MO | Washington University | St Louis63110 | NCT05768139 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05768139 | Map |
| OH | UH Cleveland Medical Center | Cleveland44106 | NCT05768139 | Map |
| OH | Stefanie Spielman Comprehensive Breast Center | Columbus43212 | NCT05768139 | Map |
| OR | Providence Cancer Institute Franz Clinic | Portland97213 | NCT05768139 | Map |
| TN | The West Clinic, PLLC dba West Cancer Center | Germantown38138 | NCT05768139 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT05768139 | Map |
| TX | Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas75246-2092 | NCT05768139 | Map |
| TX | University of Texas Southwestern | Dallas75390 | NCT05768139 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT05768139 | Map |
| TX | START San Antonio | San Antonio78229 | NCT05768139 | Map |
| UT | START Mountain Region | West Valley City84119 | NCT05768139 | Map |
| VA | USO-Virginia Cancer Specialists, PC | Fairfax22031 | NCT05768139 | Map |
[14C]-STX-478 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P1/P2 | 1 | 1 |
Recruiting [14C]-STX-478 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05768139 | PIKALO-1First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | P1/P2 | Breast Cancer | 880 | Apr 2023 |
[14C]-STX-478 clinical trials by indication
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06901336 | — | P1 | completed | A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants |
Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05768139 | PIKALO-1 | P1/P2 | recruiting | First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors |
All [14C]-STX-478 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05768139 | PIKALO-1 | First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | P1/P2 | recruiting | 880 | Eli Lilly and Company | Apr 2023 |
| NCT06901336 | A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants | P1 | completed | 8 | Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company | Mar 2025 |
[14C]-STX-478 clinical trials: frequently asked questions
- How many [14C]-STX-478 clinical trials are there?
- 2 [14C]-STX-478 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 1 is marked completed.
- Are [14C]-STX-478 clinical trials recruiting in 2026?
- Yes — 1 [14C]-STX-478 trial is actively recruiting in 2026, with 24 U.S. sites across 16 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is [14C]-STX-478 being studied for?
- [14C]-STX-478 is being studied for Breast Cancer, Healthy, Solid Tumors, Adult. The trials are grouped by indication on this page.
- What phase is [14C]-STX-478 in?
- [14C]-STX-478 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors [14C]-STX-478 clinical trials?
- The lead sponsor across the most [14C]-STX-478 trials is Eli Lilly and Company, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming [14C]-STX-478as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: